Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADOPT
2024-511252-41-00Phase 3Authorised
- Sponsor
- University Medical Center Groningen
- Start
- Jul 2024
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised trial of leuprolide in prostate cancer (PCa) (2 arms), sponsored by University Medical Center Groningen. Primary endpoint: 2-year metastases progression-free survival. Planned start Jul 2024; status: authorised.
02
Drugs
leuprolide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2024-511252-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511252-41-00.